TIRADS Guideline Summary

Overview of TIRADS

The American College of Radiology recommends using the TIRADS system, a standardized ultrasound-based risk stratification system, to assess malignancy risk in thyroid nodules and guide decisions about fine needle aspiration (FNA) biopsy 1

Solid nodules carry higher malignancy risk than cystic nodules, according to the International Journal of Surgery 2
Cystic nodules or those with <10% solid component are typically benign, as stated by the International Journal of Surgery 2
Mixed nodules require assessment of the solid component percentage, as noted by the International Journal of Surgery 2
Isoechoic nodules have intermediate risk, as reported by Praxis Medical Insights 3
Smooth, well-defined borders are associated with benign nodules, according to Praxis Medical Insights 3

The American College of Radiology TIRADS system uses nodule size thresholds that vary by risk category to determine when FNA is indicated, with recommendations including FNA for TR3 nodules ≥1.5 cm, TR4 nodules ≥1.0 cm, and TR5 nodules ≥0.5 cm 1, 4

The American College of Radiology recommends performing thyroid function tests, including TSH measurement, as the initial laboratory assessment 1, 3
US-guided FNA is recommended for nodules meeting size criteria, as stated by the International Journal of Surgery and Praxis Medical Insights 2, 3

The ACR TIRADS system has limitations, including a 5-10% false-negative rate for FNA, as noted by Praxis Medical Insights 3
TIRADS cannot distinguish follicular adenoma from follicular carcinoma, requiring histologic assessment of capsular or vascular invasion, as reported by the International Journal of Surgery 2
Cytology rarely provides reliable cancer subtype information, according to Reviews in Endocrine and Metabolic Disorders 5

The American College of Radiology recommends ultrasound follow-up in 6-12 months for nodules not meeting FNA criteria, as stated by Praxis Medical Insights 4, 3
Continued surveillance at 12-24 month intervals is recommended for benign FNA results, as noted by Praxis Medical Insights 3

The American College of Radiology recommends surveillance with ultrasound follow-up for thyroid nodules less than 0.5 cm classified as TI-RADS 3 or 4, rather than fine needle aspiration, regardless of suspicious ultrasound features 6

Small papillary thyroid carcinomas (<1 cm) have lower potential for relapse after treatment, making their clinical significance generally low 6
Avoiding FNA in nodules <1 cm prevents overdiagnosis of clinically insignificant papillary microcarcinomas that do not impact mortality or quality of life 6, 7

Consider FNA even for nodules <0.5 cm if high-risk clinical factors are present, including history of head and neck irradiation, which increases malignancy risk approximately 7-fold 8
Consider FNA for nodules <0.5 cm if high-risk clinical factors are present, including family history of thyroid cancer, particularly medullary carcinoma or familial syndromes 8
Consider FNA for nodules <0.5 cm if suspicious cervical lymphadenopathy is present on ultrasound examination 6
Consider FNA for nodules <0.5 cm if the nodule is located subcapsularly, which increases risk of extrathyroidal extension 6
Consider FNA for nodules <0.5 cm if the patient is <15 years old, which carries higher baseline malignancy probability 8

Do not perform FNA based solely on suspicious ultrasound features if size criteria are not met, as this leads to overdiagnosis without improving outcomes 6, 7
Recognize that current guidelines create a paradox for small high-risk nodules: FNA is not recommended for nodules <1 cm, yet nonsurgical treatments like thermal ablation require confirmed malignancy 8, 7
Understand that cytology rarely provides reliable cancer subtype information, limiting the utility of FNA in very small nodules even when performed 8